Blue Trust Inc. Has $10.93 Million Position in Johnson & Johnson (NYSE:JNJ)

Blue Trust Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,875 shares of the company's stock after purchasing an additional 2,662 shares during the period. Blue Trust Inc.'s holdings in Johnson & Johnson were worth $10,925,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Tallon Kerry Patrick purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $290,000. Capital & Planning LLC increased its position in Johnson & Johnson by 13.6% in the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock worth $221,000 after purchasing an additional 183 shares during the last quarter. Brighton Jones LLC raised its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $85,886,000. Finally, KLCM Advisors Inc. grew its stake in shares of Johnson & Johnson by 2.0% in the 4th quarter. KLCM Advisors Inc. now owns 7,186 shares of the company's stock valued at $1,039,000 after buying an additional 140 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on JNJ. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Finally, Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.92 during midday trading on Friday, hitting $149.81. The company had a trading volume of 22,591,152 shares, compared to its average volume of 7,993,824. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The business's 50 day simple moving average is $154.07 and its two-hundred day simple moving average is $153.65. The stock has a market cap of $360.44 billion, a PE ratio of 16.66, a P/E/G ratio of 2.27 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.47%. Johnson & Johnson's dividend payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.